SCHEMBL10329914

SCHEMBL10329914

CN1SC[C@@](C)(c2cc3[nH]c(-c4ccccc4)cc3cc2F)NC1=N

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
VCP P55072 10/20 0.34
CYP19A1 P11511 4/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
F2 P00734 2/20 0.33
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32
SENP7 Q9BQF6 1/20 0.32
SENP6 Q9GZR1 1/20 0.32
F10 P00742 1/20 0.31
PLAU P00749 1/20 0.31
PLAT P00750 1/20 0.31
KLKB1 P03952 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17507404 0.68 ALDH1A1 (0.38) NPC1RAB9AMAPTKMT2AALDH1A1
SCHEMBL4568269 0.65 NPC1 (0.53) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL10329929 0.65 BACE1 (0.30)
SCHEMBL10329145 0.65 BACE1 (0.40) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL12124985 0.64 NPC1 (0.75) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL4568282 0.64 NPC1 (0.47) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL4568268 0.63 NPC1 (0.50) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL4568264 0.63 ALDH1A1 (0.58) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL4568291 0.63 NPC1 (0.53) NPC1RAB9AMAPTKDM4EMEN1
SCHEMBL10329944 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120183563-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME LLC 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120183563-A1 IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS AND THEIR USE BACE1, BACE2, APP NPC1 677/4885RAB9A 1023/4885MAPT 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.